Using transcutaneous vagus nerve stimulation (tVNS) for 2 minutes, 3 times per day reduces inflammation markers in the bloodstream and improves symptoms from psoriatic arthritis and ankylosing spondylitis. In addition to other studies showing benefits in rheumatoid arthritis and Crohn’s disease, this study provides additional evidence that tVNS may be an effective anti-inflammatory therapy for a variety of autoimmune disorders.
Interim tVNS Clinical Trial Results Show Reduced Deaths for Hospitalized COVID-19 Patients
Nemechek Technologies is a fast growing company with unique expertise in neuromodulation that is positioned to provide a variety of solutions for individuals with both acute and chronic symptoms from COVID-19 infection and other conditions.
We are currently looking for interested partners to fulfill our mission and make a difference in the lives of COVID-19 infected individuals.
innovative bioelectric technology
As the Coronavirus pandemic continues to spread worldwide, it is becoming readily apparent that modern medicine is not prepared to fight the unique disease processes triggered by COVID-19 infection. Nemechek Technologies is a small company with cutting edge expertise and a clear vision of the medical needs of patients afflicted with COVID-19.
Our company’s vision for COVID-19 therapies arose from Dr. Nemechek’s 20 years experience as an HIV expert, combined with his recent discoveries involving the reversal of nervous system damage though the proper regulation of inflammation within the body. Dr. Nemechek believes that the future of health maintenance will be based on minimizing the stress of systemic inflammation.
Our Mission is to demonstrate that vagus nerve stimulation is an effective therapy for both acute and convalescent COVID-19 patients and to produce high quality transcutaneous vagus nerve stimulators for their use. Beyond COVID-19, vagus nerve stimulation and related products such as HRV monitors have potential for other autonomic health and wellness applications.
How the Vitality Neuromodulator Can Aid in the Fight Against COVID-19
Patients hospitalized with COVID-19 are predominantly dying of respiratory failure due to a surge of pro-inflammatory protein molecules called cytokines that regulate inflammation. In some COVID-19 patients, an excessive inflammatory reaction known as a “cytokine storm” will trigger acute respiratory distress syndrome. This severe form of lung injury is why many patients require mechanical ventilation.
A potential solution to this deadly, unregulated immune response may be a mild electrical current applied to the vagus nerve. Dr. Nemechek’s method, known as transcutaneous auricular vagus nerve stimulation (taVNS), delivers a barely perceptible micro-current through a specially designed clip that fits comfortably on the ear.
Nemechek Technologies has applied for an Emergency Use Application (EUA) from the FDA as well as an Emergency Use Listing (EUL) from the World Health Organization to use vagus nerve stimulation as adjunctive therapy in persons struggling from the acute or chronic symptoms of COVID-19 infection.
Research: Vagus nerve stimulation as a potential adjuvant to behavioral therapy for autism and other neurodevelopmental disorders
The authors of this paper discuss how VNS paired with behavioral therapy may represent a potential new approach to enhance rehabilitation that could significantly improve the outcomes of individuals with neurodevelopmental disorders. ‘
More research examining the potential role of vagus nerve stimulation continues to be published. This paper reviews the potential clinical benefits of using transcutaneous vagus nerve stimulation as adjunctive therapy for COVID-19. The authors conclude, “Vagal neurostimulation has a wide field of therapeutic benefit for patients and should be combined with the best current medical strategies. The development of non-invasive vagal nerve stimulation (t-VNS), a non-pharmacological adjuvant, may help reduce the burden of COVID-19 and deserve to be investigated.” [emphasis added]
PR: Vagus Nerve Stimulation Associated with Fewer Deaths in Hospitalized COVID-19 Patients, Dec 2, 2020
OVERLAND PARK, KANSAS, UNITED STATES, December 2, 2020 /EINPresswire.com/ — Nemechek Technologies is proud to announce publication of a peer-reviewed research article by its CEO, Patrick Nemechek D.O. Entitled, ‘Transcutaneous Vagus Nerve Stimulation is Associated with Lower Mechanical Ventilation and Mortality in COVID-19 Patients: An interim Safety Analysis’, the study reveals that transcutaneous vagus nerve stimulation (tVNS) is safe and potentially beneficial for hospitalized patients with COVID-19 pneumonia. Patients meeting clinical criteria received tVNS therapy for 5 minutes 2-4 times per day with the Nemechek Technologies Vitality Smartcable® neuromodulator. Patient outcomes included infrequent use of mechanical ventilation, and a high rate of survival.
OVERLAND PARK, Kan., July 28, 2020 /PRNewswire/ — Nemechek Technologies has applied to the World Health Organization (WHO) for Emergency Use Listing (EUL) of its Vitality Smartcable device. In January, the WHO Director-General declared that the coronavirus outbreak constituted an international public health emergency. The EUL procedure was developed to help member states choose diagnostics, vaccines, and therapeutics based on available quality, safety, and performance data. The Vitality Smartcable is a transcutaneous auricular vagus nerve stimulator (taVNS) operated by a smartphone and is capable of significantly lowering inflammation through electronical impulses delivered through a clip that fits comfortably on the ear. Dr. Nemechek says, “Stimulation